drugset / Trial / NCT07302035
A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women
Phase 1
Not yet recruiting
30 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Huashan Hospital · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase Ia single-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, Pharmacokinetic of GenSci142 in Chinese healthy women.
Timeline
- Start
- 2025-12
- Primary completion
- 2026-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GenSci142 | Unknown | — | Other |